Cristcot HCA LLC · NDA 220054
YN U.S. FOOD & DRUG ADMINISTRATION NDA 220054 COMPLETE RESPONSE Cristcot HCA LLC Attention: Jennifer Davagian President 9 Damonmill Square Suite 4A Concord, MA 01742 Dear Jennifer Davagian: Please re…
- Letter date
- 10/19/2026
- File name
- CRL_NDA220054_20261019.pdf
- Letter year
- 2026
- Approval status
- Unapproved
- Approver name
- ©) (4)
- Company rep
- Jennifer Davagian
- Company address
- Suite 4A Concord, MA 01742
- Company name
- Cristcot HCA LLC
- Letter type
- COMPLETE RESPONSE
- Text
¢ YN U.S. FOOD & DRUG ADMINISTRATION NDA 220054 COMPLETE RESPONSE Cristcot HCA LLC Attention: Jennifer Davagian President 9 Damonmill Square Suite 4A Concord, MA 01742 Dear Jennifer Davagian: Please refer to your new drug application (NDA) dated and received December 19, 2025, and your amendments, submitted pursuant to for hydrocortisone acetate (HCA) rectal (b) (4) suppository. We also acknowledge receipt of your amendments received on October 15, 2026, October 16, 2026, and October 19, 2026, which were not reviewed for this action. You may incorporate applicable sections of the amendments by specific reference as part of your response to the deficiencies cited in this letter. We have completed our review of this application, as amended, and have determined hat we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address hese issues. CLINICAL To support substantial evidence of effectiveness of your product, you submitted data rom a single randomized, double-blind, placebo-controlled phase 3 trial, Trial CHS1221 and proposed to rely on the Agency’s previous findings of safety and effectiveness of he listed drug (LD), Cortenema (hydrocortisone, retention enema), and submitted published literature as supportive evidence of safety and effectiveness.’ We have reviewed your application and concluded that, because of the following deficiencies, your application does not provide substantial evidence of effectiveness for HCA rectal suppository for oe . Many of 1 See NDA 220054, 2.5 Clinical Overview Reference ID: 5888200 NDA 220054 Page 2 these deficiencies were communicated in the Discipline Review Letter, dated September 11, 2026,? and have not been addressed. (1) Trial CHS1221 does not provide substantial evidence of effectiveness as a single adequate and well-controlled trial because of the following deficiencies: a) When the primary endpoi int of clinical remission at Day 29 was analyzed in accordance with the pre-specified statistical analysis plan (SAP), Trial CHS1221 did not demonstrate a statistically significant difference between the HCA rectal suppository treatment arms and placebo. Furthermore, there were no nominally significant differences between HCA rectal suppository treatment arms and placebo for the key secondary endpoints of reduction in stool frequency at Day 15 and Day 29. The results of Trial CHS1221 do not reliably demonstrate that the observed differences between treatment arms are attributable to HCA rectal suppository rather than to chance. b) To address your concern during the trial, you imple ‘or use of prohibited exogenous corticosteroids mented “[rjules based on endocrinology principles that allow the cortisol results ([pharmacokinetic] PK and [adrenocorticotropic hormone] ACTH Stimulation) to be evaluated along with treatment assignment to identify viol lators of the protocol and use of prohibited exogenous corticosteroids.” When these “endocrinology rules” are applied, the analyses for the primary and some secondary endpoints produced p- values <0.05 (unadjusted rules" are not adequately bias the results in favor o for multiplicity). However, the five "endocrinology supported and their application is highly likely to HCA rectal suppository. i. The five "endocrinology rules" are not adequately supported by the available scientific interpretation of col stimulation testing evidence in your application. The rules rely on the rtisol measurements collected as part of ACTH and PK assessments at different times and under different conditions. You state that the rules are based on "established principles of endocrinology,"* however, the ACTH stimulation test is used to make the diagnosis of adrenal insufficiency, not to identify exogenous corticosteroid use.° Additionally, you did not provide adequate justification to support that the rules can reliably identify exogenous corticosteroid use (e.g., comparison to a reference standard, sensitivity and specificity of the rules). Moreover, there are multiple factors other than exogenous corticosteroids that could influence cortisol measurements (e.g., sleep patterns, stress, timing of 2 See also FDA Pre-NDA Meeting Minutes dated February 3, 2025, FDA Meeting Minutes dated July 29, 2025, and FDA Filing Communication — Filit ing Review Issues Identified dated March 3, 2026. 3 BDRM Meeting November 18, 2024, page 5 42.7.3 Summary of Clinical Efficacy, page 100 5 See [Cosyntropin] at https://www.accessd jata.fda.gov/scripts/cder/daf/ U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov Reference ID: 5888200 NDA 220054 Page 3 measurement, illness, nutrition status, concomitant drugs, disease activity, sampling preparation and methods, dosage of ACTH, type of assay, and other physiological and external factors) and plausibly explain the observed ACTH stimulation test and PK assessment data. The development and application of the "endocrinology rules" are highly likely to bias the results in favor of HCA rectal suppository regardless of whether unblinded efficacy data were available at the time the rules were developed. The rules were not pre-specified in the SAP and were developed by personnel who were unblinded to treatment assignment.® Identifying suspected protocol violations related to prohibited corticosteroid use based on retrospectively applied rules developed by personnel unblinded to treatment assignment, rather than through prospective data collection and reporting of subject medication use, is highly likely to introduce bias. In addition, the rules were applied asymmetrically (i.e., four of the five rules were applicable only to the placebo arm and not to the treatment arms), disproportionately affecting the placebo arm. Of the ™subjects ( % of the full analysis set) categorized as treatment failures in the primary analysis using these rules, 18 were from the placebo arm. This differential application across arms substantially reduced the observed placebo response rate (i.e., the number of observed placebo responders decreased from 9 to 1) while having no effect on the observed HCA rectal suppository response rate in either of the HCA rectal suppository treatment arms. This asymmetric application may artificially inflate the apparent treatment effect and is highly likely to bias the efficacy results in favor of HCA rectal suppository, potentially inflating the type | error rate.” (2) You have not established that it is scientifically appropriate to rely on the Agency’s previous findings of effectiveness for the listed drug, Cortenema, or to rely on published literature for approval because of the following deficiencies: ® See BDRM Meeting August 20, 2024, page 5, “At the completion of the study and data lock, and prior to the data analysis for efficacy, the study treatment assignment will be given to with the PK and ACTH blood data for the completion of the safety, PK and ae @ analysis of the study data.” See also BDRM Meeting November 18, 2024, page 5, “ prepared Rules based on endocrinology principles that allow the cortisol results (PK and ACTH Stimulation) to be evaluated along with treatment assignment to identify violations of the protocol and use of prohibited exogenous corticosteroids.” 7 Excluding these tH subjects, instead of imputing them as non-responders, is also inappropriate as analyses excluding subjects based on post-randomization outcomes do not provide randomized comparisons and are likely to introduce bias. U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov Reference ID: 5888200 NDA 220054 Page 4 a) Although you previously agreed that clinical trials would be needed to establish the efficacy and safety of your product,® your submission states that the results of Trial CHS1221 are supported by "the established efficacy of the listed drug [LD], Cortenema"? and that you have established a bridge to Cortenema “through a relative bioavailability study (CINC-2015-BA).”'° We have determined that CINC-2015-BA does not adequately support a scientific bridge between the proposed HCA 90 mg rectal suppository and Cortenema (hydrocortisone retention enema, 100 mg/60 mL) to rely on the Agency’s previous findings of effectiveness for Cortenema. Specifically, your product demonstrated a Cmax approximately 51% lower than Cortenema, raising concerns that reliance on Cortenema is not scientifically justified. Considering the results of CINC-2015-BA, the anticipated differences in local distribution and absorption between your product and Cortenema, and the results of Trial CHS1221 as described above, the available data are not sufficient to establish a scientific bridge to support reliance on the Agency's previous findings of effectiveness for Cortenema. b) Your submission includes published literature, “ me ett AS described previously, '* the literature references include studies that differ substantially from Trial CHS1221 in formulation, dosage form, dosing regimen, treatment duration, patient population, and efficacy endpoints. Additionally, you have not provided an adequate scientific bridge to Cortenema, as described above, or other products described in the literature to support reliance on literature to support the effectiveness of your product. Information needed to resolve the deficiencies: To resolve the above-noted deficiencies, we recommend that you conduct one adequate and well-controlled trial and provide confirmatory evidence, or conduct two adequate and well-controlled trials, to provide substantial evidence of effectiveness for HCA rectal suppository for the . We also recommend that you use the existing data to identify the root cause of the lack of effectiveness observed in Trial CHS1221, which could be multifactorial (e.g., dosage, 8 See Meeting Minutes, dated August 27, 2014, page 8, “FDA clarified that plasma exposure data would only provide information on systemic exposures, but that it would not be sufficient to establish the safety or efficacy of [the Applicant's] product for the proposed indication” and “The FDA and Sponsor agreed that clinical trials will be required to establish efficacy and safety of the drug-device combination product, including assessment of any device-related adverse events.” See also the response to the Discipline Review letter, dated September 15, 2026, page 12, “the efficacy of the suppository is not directly supported by bioequivalence due to the 50% lower Cmax and requires some clinical demonstration.” ° Summary of Clinical Efficacy, page 6 10 2.5 Clinical Overview, page 5. See also Table 2. Overview of 505(b)(2) NDA Application Data, which describes the reliance on the previous findings of safety and effectiveness from Cortenema (NDA 016199). 112.5 Clinical Overview, page 20 12 Refer to FDA Pre-NDA Meeting Minutes dated February 3, 2025, and Meeting Minutes dated July 29, 2025; Refer to FDA Filing Communication — Filing Review Issues Identified dated March 3, 2026. U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov Reference ID: 5888200 NDA 220054 Page 5 drug product formulation, patient population), to inform your future development program. If you elect to rely on a single adequate and well-controlled trial plus confirmatory evidence, we refer you to FDA's draft guidance for industry Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products (June 2026). As described in the guidance, when strong confirmatory evidence is not available, a single adequate and well-controlled trial intended to provide substantial evidence of effectiveness would generally be expected to be highly persuasive. Specifically, such a trial would generally be expected to: use a design that is generalizable and relevant to clinical practice; employ a clinically meaningful primary endpoint with sufficient power to convincingly demonstrate an effect; generate primary analysis results that are clinically and statistically highly persuasive; generate results that are supportive across distinct prespecified secondary endpoints; demonstrate consistency of results across important trial subsets; and have high-quality conduct with comprehensive follow-up, minimal missing data, and be robust to plausible violations in assumptions. We recommend that you request a meeting with the Division to discuss your proposed approach to providing substantial evidence of effectiveness prior to initiating any new trial(s) and completing such trial(s) before resubmitting the application. Alternatively, if you intend to rely on the Agency’s previous findings of effectiveness of a proposed listed drug and/or rely on literature, you may consider modifications to your drug product to increase the likelihood of establishing an adequate scientific bridge to the proposed listed drug and/or products described in the literature. PRODUCT QUALITY (b) (4) U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov Reference ID: 5888200 NDA 220054 Page 6 PRESCRIBING INFORMATION We reserve comment on the proposed labeling until the application is otherwise adequate. We encourage you to review the labeling review resources on the Prescription Drug Labeling Resources ‘* and Pregnancy and Lactation Labeling Final Rule “4 websites, including regulations and related guidance documents and the Selected Requirements for Prescribing Information (SRPI) - a checklist of important format items from labeling regulations and guidances. 13 14 U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov Reference ID: 5888200 NDA 220054 Page 7 CARTON AND CONTAINER LABELING We reserve comment on the proposed labeling until the application is otherwise adequate. PROPRIETARY NAME Please refer to our correspondence dated May 28, 2026, which addresses the proposed proprietary name, ©. This name was found conditionally acceptable pending approval of the application in the current review cycle. Please resubmit the proposed proprietary name when you respond to all of the application deficiencies that have been identified in this letter. SAFETY UPDATE When you respond to the above deficiencies, include a safety update as described at 21 CFR 314.50(d)(5)(vi)(b). The safety update should include data from all nonclinical and clinical studies/trials of the drug under consideration regardless of indication, dosage form, or dose level. (1) Describe in detail any significant changes or findings in the safety profile. (2) When assembling the sections describing discontinuations due to adverse events, serious adverse events, and common adverse events, incorporate new safety data as follows: e Present new safety data from the studies/clinical trials for the proposed indication using the same format as in the original submission. e Present tabulations of the new safety data combined with the original application data. e Include tables that compare frequencies of adverse events in the original application with the retabulated frequencies described in the bullet above. e For indications other than the proposed indication, provide separate tables for the frequencies of adverse events occurring in clinical trials. (3) Present a retabulation of the reasons for premature trial discontinuation by incorporating the drop-outs from the newly completed trials. Describe any new trends or patterns identified. (4) Provide case report forms and narrative summaries for each subject who died during a clinical trial or who did not complete a trial because of an adverse event. In addition, provide narrative summaries for serious adverse events. U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov Reference ID: 5888200 NDA 220054 Page 8 (5) Describe any information that suggests a substantial change in the incidence of common, but less serious, adverse events between the new data and the original application data. (6) Provide updated exposure information for the clinical studies/trials (e.g., number of subjects, person time). (7) Provide a summary of worldwide experience on the safety of this drug. Include an updated estimate of use for drug marketed in other countries. (8) Provide English translations of current approved foreign labeling not previously submitted. ADDITIONAL COMMENTS We have the following comments/recommendations that are not approvability issues: 1) (b) (4) OTHER Within one year after the date of this letter, you are required to resubmit or take other actions available under 21 CFR 314.110. If you do not take one of these actions, we may consider your lack of response a request to withdraw the application under 21 CFR 314.65. You may also request an extension of time in which to resubmit the application. A resubmission must fully address all the deficiencies listed in this letter and should be clearly marked with "RESUBMISSION' in large font, bolded type at the beginning of the cover letter of the submission. The cover letter should clearly state that you consider this resubmission a complete response to the deficiencies outlined in this letter. A partial response to this letter will not be processed as a resubmission and will not start a new review cycle. U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov Reference ID: 5888200 NDA 220054 Page 9 You may request a meeting or teleconference with us to discuss what steps you need to take before the application may be approved. If you wish to have such a meeting, submit your meeting request as described in the guidance for industry Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products. The product may not be legally marketed until you have been notified in writing that this application is approved. If you have any questions, contact Cay Sincerely, {See appended electronic signature page} ©) (4) Center for Drug Evaluation and Research U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov Reference ID: 5888200 Signature Page 1 of 1 This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record. (b) (4) 10/19/2026 01:03:48 PM Reference ID: 5888200
- Approver center
- Center for Drug Evaluation and Research
- Application number
- NDA 220054
